Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
Non-Hodgkin's Lymphoma
DRUG: Iodine-131 Anti-B1 Antibody
The endpoints of the study are to determine the response rate, complete response rate, duration of response, time to progression, time-to-treatment failure, safety, and survival following Iodine-131 Anti-B1 Antibody therapy in patients with NHL who previously responded (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy.